Erythroleukemia: an Update

Olga K. Weinberg, Daniel A. Arber

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of the Review: Acute erythroleukemia (AEL) is a rare form of acute myeloid leukemia recognized by erythroblastic proliferation. Many controversies remain around diagnosis influencing prognostic and therapeutic implications relating to this unique leukemia subset. Recent Findings: The 2016 WHO classification includes more clear and restrictive diagnostic criteria for AEL. Primary acute erythroid leukemia is associated with complex and high-risk karyotypes including chromosomes 5q and 7q abnormalities. Mutational data shows that AEL is characterized by far lower NPM1 and FLT3-ITD mutation rates and higher mutational rates in TP53 compared with other AML subtypes. Hypomethylating agents have shown therapeutic value in AEL. Summary: In this article, we discuss the evolving diagnostic concepts of erythroleukemia, genomics, clinical outcome, and promising therapeutic targets through an appraisal of the current literature.

Original languageEnglish (US)
Article number69
JournalCurrent oncology reports
Volume23
Issue number6
DOIs
StatePublished - Jun 2021

Keywords

  • Acute erythroid leukemia
  • Clinical presentation
  • Genomics
  • Molecular mutations

ASJC Scopus subject areas

  • Oncology

Fingerprint

Dive into the research topics of 'Erythroleukemia: an Update'. Together they form a unique fingerprint.

Cite this